VIDEO from Novartis Available on thenewsmarket.com: Novartis Presents Data about Tasigna in Treatment of Patients with Newly Dia

NEW YORK, Dec. 6, 2010 /PRNewswire/ -- See video from Novartis at:

http://www.thenewsmarket.com/Releases/StoryDetailPage.aspx?GUID=b76c2552-3cd3-4727-8f46-ef825bcb66d4#

Novartis announced 24-month data showing that Tasigna® (nilotinib) continues to surpass Glivec® (imatinib)* in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase1. These new data, from the first Phase III comparison of the two oral therapies as initial treatment for this blood cancer, were presented at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH) in Orlando, Florida. Available video includes an edited package, product shots and soundbites.

About thenewsmarket.com

thenewsmarket.com delivers free broadcast- and streaming-quality video and multimedia content directly to media around the world, 24/7. More than 25,000 media outlets in 190+ countries use thenewsmarket.com, including the AP, BBC, CNBC, CNN, France 24, N24, nytimes.com, RAI, TVE, ZDF and a lot more.  

Registered journalists can preview and download video, audio, text, graphics and photos at http://www.thenewsmarket.com.

If not already registered, please take a moment to sign up - registration is quick, easy and free: http://www.thenewsmarket.com/registration

We are always happy to receive your feedback, suggestions or enquiries.  Email us at [email protected]

Story Id: 20823

SOURCE thenewsmarket.com

Suggested Articles

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.

The platform, which is in use at companies including Agios, enables researchers to simultaneously detect DNA and protein changes in single cells. 

As Urovant gears up for the launch of vibegron, its overactive bladder treatment, it is pushing the same drug through the clinic in other indications.